Harnessing the Benefits of Externally Controlled Clinical Trials (ECTs) to Accelerate Development of Better Medicines
Parexel experts from regulatory, epidemiology and biostatistics discuss the use of external control arms (ECAs) as an alternative to randomized controlled trials (RCTs) to accelerate clinical development. Based on literature analysis, as well as available EMA and FDA guidelines, they provide a detailed assessment of ECAs pros and cons.
The digital era has enhanced the potential for real-world evidence (RWE) in regulatory decision-making, as demonstrated during the COVID-19 pandemic. Artificial intelligence (AI) could play a crucial role in analyzing RWE data to identify trends and important factors to control, potentially expanding ECA applications to dosage optimization, new administration routes, and accelerated treatment development. However, ECA implementation based on RWD still remains limited due to challenges such as ensuring data robustness, matching patient populations, and controlling bias.
What is more, regulatory acceptance of ECAs also requires thorough justification and early discussions with authorities to address potential biases and confounding factors. Therefore, while ECAs have the potential to streamline drug development and bring treatments to patients faster, further advancements in regulatory approaches, methodologies, and technologies are necessary to realize this goal fully.
Related Insights
Blog
Regulatory submissions as a source of insight: How AI can amplify the value of our work
Jul 15, 2026
Blog
The future of drug development: Leveraging EMA support for use of alternative nonclinical approaches
Jun 6, 2024
Blog
Regulatory acceptability of AI: Current perspectives
Mar 7, 2024
Case Study
Speed meets strategy: Delivering a critical FDA 1572 package in just seven days
Sep 9, 2026
Blog
Actioning the commitment letter: The PDUFA VIII changes that matter most to sponsors
Aug 25, 2026
Blog
Data without borders: Assessing China-only evidence for EMA approval – insights from ex-EMA and seasoned subject matter experts
Aug 19, 2026
Blog
The Next Frontier of ADC Development: Navigating an Evolving Regulatory Landscape
Aug 12, 2026
Webinar
From APAC to Global: Designing Data that Travels
Jul 16, 2026
CTB Blog
Modeling & simulation and artificial intelligence for early drug development
Jul 14, 2026
Blog
Accelerating first-in-human studies: Why the FDA’s Expedited IND pilot signals a new era for early development
Jul 6, 2026
Blog
Human-centered AI - A dual-layer model for clinical research excellence
Jul 1, 2026
Blog
The connected submission - How AI, automation, and intelligence are changing the regulatory ecosystem
Jul 1, 2026
Related Insights
Blog
Regulatory submissions as a source of insight: How AI can amplify the value of our work
Jul 15, 2026
Blog
The future of drug development: Leveraging EMA support for use of alternative nonclinical approaches
Jun 6, 2024
Blog
Regulatory acceptability of AI: Current perspectives
Mar 7, 2024
Case Study
Speed meets strategy: Delivering a critical FDA 1572 package in just seven days
Sep 9, 2026
Blog
Actioning the commitment letter: The PDUFA VIII changes that matter most to sponsors
Aug 25, 2026
Blog
Data without borders: Assessing China-only evidence for EMA approval – insights from ex-EMA and seasoned subject matter experts
Aug 19, 2026
Blog
The Next Frontier of ADC Development: Navigating an Evolving Regulatory Landscape
Aug 12, 2026
Webinar
From APAC to Global: Designing Data that Travels
Jul 16, 2026
CTB Blog
Modeling & simulation and artificial intelligence for early drug development
Jul 14, 2026
Blog
Accelerating first-in-human studies: Why the FDA’s Expedited IND pilot signals a new era for early development
Jul 6, 2026
Blog
Human-centered AI - A dual-layer model for clinical research excellence
Jul 1, 2026
Blog
The connected submission - How AI, automation, and intelligence are changing the regulatory ecosystem
Jul 1, 2026